Class summary at a glance.

Every drug in the Aromatase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $132.6Mcombined across class
Total Rx claims: 4.2M1.3M unique beneficiaries
Generic mfrs (active): 20across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Anastrozole

Brand: ARIMIDEX · 2.6M Part D claims (CY24) · 818K beneficiaries · First FDA approval: 2010-06-22

8 generic mfrs 0 plans require PA

Low NADAC$0.139

→

Avg plan cost$2.90

Part D spend $54.5M 21× spread, current vs floor

Class share

41%

of class CY24 spend

View profile →

Exemestane

Brand: Aromasin · 339K Part D claims (CY24) · 103K beneficiaries · First FDA approval: 1999-10-21

7 generic mfrs 0 plans require PA

Low NADAC$0.593

→

Avg plan cost$4.43

Part D spend $46.3M 7× spread, current vs floor

Class share

35%

of class CY24 spend

View profile →

Letrozole

Brand: Femara · 1.3M Part D claims (CY24) · 402K beneficiaries · First FDA approval: 1997-07-31

5 generic mfrs 0 plans require PA

Low NADAC$0.146

→

Avg plan cost$2.39

Part D spend $31.7M 16× spread, current vs floor

Class share

24%

of class CY24 spend

View profile →

Anastrozole Tablets

Brand: Anastrozole · — Part D claims (CY24) · First FDA approval: 2019-02-28

Brand-only (no generics)

Low NADAC$0.139

→

Avg plan cost$0.139

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Letrozole Tablets

Brand: Letrozole · — Part D claims (CY24) · First FDA approval: 2018-11-14

Brand-only (no generics)

Low NADAC$0.146

→

Avg plan cost$0.146

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.